# US 2025/0145593 A1 · Dantrolene prodrugs and methods of their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145593 A1
- Document ID: US20250145593A1
- Status: Published application
- Kind: A1
- Application number: 18/918,855
- Filed: 2024-10-17
- Published: 2025-05-08
- Earliest claimed: 2017-10-20
- Assignees: Eagle Research Labs Limited
- Applicants: Eagle Research Labs Limited
- Inventors: Charles WESCOTT; Adrian HEPNER; Alyssa LARSON
- Web page: https://patentgrep.com/patent/US20250145593A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 25/00: Drugs for disorders of the nervous system
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The disclosure is directed to dantrolene prodrugs, compositions thereof, and methods of their use in the treatment of disease.

## Claims

### Claim 1

A pharmaceutical composition comprising the compound of formula I
wherein
R is —P(O)(OR1)(OR2);
R1 is H, —C1-26alkyl, aryl, —C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or —C1alkOC(O)OC1-26alkyl; and
R2 is —C1-26alkyl, aryl, —C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or —C1alkOC(O)OC1-26alkyl;
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is H.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is —C1-26alkyl.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is aryl.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is —C1-6alkC(O)O—C1-26alkyl.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is —C1alkOC(O)C1-26alkyl.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein R1 is —C1alkOC(O)OC1-26alkyl.

### Claim 8 (depends on 2)

The pharmaceutical composition of claim 2, wherein R2 is —C1-26alkyl or aryl.

### Claim 9 (depends on 2)

The pharmaceutical composition of claim 2, wherein R2 is —C1-6alkC(O)O—C1-26alkyl.

### Claim 10 (depends on 2)

The pharmaceutical composition of claim 2, wherein R2 is —C1alkOC(O)C1-26alkyl.

### Claim 11 (depends on 2)

The pharmaceutical composition of claim 2, wherein R2 is —C1alkOC(O)OC1-26alkyl.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, in the form of a pharmaceutically acceptable salt.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the excipient comprises preservative, antioxidants, and mixtures thereof.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the preservative is selected from phenol, cresol, p-hydroxybenzoic ester, chlorobutanol, and mixtures thereof.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13, wherein the antioxidant is selected from ascorbic acid, sodium pyrosulfite, palmitic acid, butylated hydroxyanisole, butylated hydroxytoluene, tocopherols, and mixtures thereof.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is a solution.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound of formula I is present at a concentration of about 1 mg/ml to about 400 mg/ml.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a stabilizer.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a buffer.

### Claim 20 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition has a pH of from about 3 to about 10.

### Claim 21 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition has an osmolarity from about 280 mOsm/L to about 310 mOsm/L.

### Claim 22 (depends on 1)

A method of treating a disorder responsive to dantrolene in a subject comprising administering to the subject the pharmaceutical composition of claim 1;
wherein the disorder is selected from malignant hyperthermia, chronic spasticity, exertional heat stroke, cardiac arrhythmias, tachycardia, atrial fibrillation, cardiac arrest, myocardial infarction, heart failure, myocardial injury, cardiomyopathy, central core disease, amyotrophic lateral sclerosis, rhabdomyolysis, Duchenne muscular dystrophy, ataxia, detrusor overactivity, overactive bladder, seizure, epilepsy, neuroleptic malignant syndrome, human stress disorder, Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, ischemia-reperfusion injury, neuronal reperfusion injury, hypoxia, cerebral aneurysm, subarachnoid hemorrhage, stroke, hyperthermia associated with drug abuse, hyperthermia associated with drug overdose, nerve agent exposure, nerve gas exposure, or acetylcholine accumulation.

### Claim 23 (depends on 22)

The method of claim 22, wherein the administration is intravenous administration.

### Claim 24 (depends on 22)

The method of claim 22, wherein the administration is intramuscular administration.

### Claim 25 (depends on 22)

The method of claim 22, wherein the administration is oral administration.

### Claim 26 (depends on 22)

The method of claim 22, wherein the administration is subcutaneous.

### Claim 27 (depends on 22)

The method of claim 22, wherein the administration is intranasal.

### Claim 28 (depends on 22)

The method of claim 22, wherein the administration is intraosseous.

### Claim 29

A pharmaceutical composition comprising the compound of formula II-A
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the compound of formula II-A is
